Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Equity Average (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Equity Average for 12 consecutive years, with $133.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average fell 43.54% year-over-year to $133.1 million, compared with a TTM value of $133.1 million through Sep 2025, down 43.54%, and an annual FY2024 reading of $288.4 million, down 23.47% over the prior year.
  • Equity Average was $133.1 million for Q3 2025 at Tandem Diabetes Care, down from $144.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $443.5 million in Q2 2022 and bottomed at $133.1 million in Q3 2025.
  • Average Equity Average over 5 years is $318.0 million, with a median of $329.7 million recorded in 2021.
  • The sharpest move saw Equity Average skyrocketed 69.02% in 2021, then tumbled 43.54% in 2025.
  • Year by year, Equity Average stood at $411.4 million in 2021, then increased by 4.74% to $430.9 million in 2022, then dropped by 27.17% to $313.8 million in 2023, then fell by 20.21% to $250.4 million in 2024, then crashed by 46.84% to $133.1 million in 2025.
  • Business Quant data shows Equity Average for TNDM at $133.1 million in Q3 2025, $144.3 million in Q2 2025, and $209.2 million in Q1 2025.